Tear Sheet

Tear Sheet

Company Profile

Vistagen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of Vistagen's CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.

Management Team

Shawn K. Singh, J.D.
Chief Executive Officer and Director
Jerrold D. Dotson, CPA
Vice President, Chief Financial Officer and Secretary
Reid Adler, J.D.
Chief Corporate Development Officer and General Counsel
Latest News
Mar 22, 2023
Mar 08, 2023



Data as of Mar 24, 2023 | 9:07 PM EDT

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Vistagen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080

Investor Relations Contact

Vistagen Therapeutics

Mark Flather
Vice President, Investor Relations
+1(650) 577-3617
mflather@vistagen.com

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.